Compare AbCellera Biologics Inc (ABCL) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Omnicom Group Inc. — how do they compare? AbCellera Biologics Inc trades at $8.95 (market cap $2.85B), while Omnicom Group Inc. trades at $85.74 (market cap $23.22B). The key difference: Omnicom Group Inc. is far larger — about 8.1× AbCellera Biologics Inc's market cap, and Omnicom Group Inc. pays a 3.78% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | OMC | |
|---|---|---|
Market Cap | $2.85B | $23.22B |
Sector | Health | Media |
52-Week High | $9.76 | $86.22 |
52-Week Low | $2.78 | $67.27 |
Enterprise Value | $2.45B | $31.30B |
Dividend Yield | — | 3.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.
The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.
Omnicom Group (OMC) trades at $85.24, up 3.31% today, with a bullish technical outlook supported by moving averages and key resistance at $86. Recent Q2 2026 earnings beat estimates with $2.65 EPS and 6.1% organic revenue growth, though net income margin remains thin at 1.74%. The company maintains a $0.80 quarterly dividend and benefits from post-merger synergies with Interpublic Group.
OMC presents a value opportunity with a low P/S of 0.96 and consensus price target of $107, but high P/E of 230.38 and integration risks post-acquisition warrant caution. Analyst sentiment is mixed with 32% buy ratings, highlighting growth potential against margin pressures and competitive threats in the advertising sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
